Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02469090 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 141
- Enrollment target
NCT02469090 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 141 participants.
The verdict
NCT02469090, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 141 participants
- Enrollment target
Study Summary
A 12-week, prospective, multi-center, randomized, double-blind, placebo controlled, Phase 3 study in L-Dopa responsive PD patients with motor fluctuations ("OFF" episodes), designed to determine the efficacy, safety and tolerability of APL-130277.
Interventions
- DRUG Placebo
- DRUG APL-130277
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2015-06-18 |
| Est. Completion | 2017-12-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02469090
The ClinicalTrials.gov registry entry for NCT02469090 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02469090 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02469090 about?
NCT02469090 is a clinical study titled "Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease". A 12-week, prospective, multi-center, randomized, double-blind, placebo controlled, Phase 3 study in L-Dopa responsive PD patients with motor fluctuations ("OFF" episodes), designed to determine the efficacy, safety and tolerability of APL-130277.
What is the current status of trial NCT02469090?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 141 participants. The study started on 2015-06-18. Estimated completion is 2017-12-11.
What interventions are being tested in trial NCT02469090?
The interventions under investigation include: Placebo (DRUG), APL-130277 (DRUG).
Who is sponsoring clinical trial NCT02469090?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.